Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co. (NYSE:BMY ) J.P. Morgan 41st Annual Healthcare Conference Call January 9, 2023 10:30 AM ET Company Participants Chris Boerner - Chief Commercial Officer Conference Call Participants Christopher Schott - J.P.

Bristol-Myers Squibb Co. (BMY) J.P. Morgan 41st Annual Healthcare Conference (Transcript)

Bristol-Myers Squibb is a high quality business that's currently on sale. It has a number of promising new drugs and carries a strong balance sheet to fund development.

Bristol-Myers Squibb: Cash Rich And Trades Under 10x PE

Amgen

Horizon Pharma

Eli Lilly

Merck

Not every stock went down in 2022. Shares in some the biggest pharmaceutical companies rose in price.

5 Top Pharma Stocks of 2022 to Buy for the Long Haul

Health Care Select Sector SPDR Fund

Profits in the sector tend to be stable even if hard times hurt earnings elsewhere, so the current high inflation and rising rates, represent a chance for the shares to shine.

Healthcare Stocks Had a Strong 2022. It Isn't Too Late to Buy.

Apple

If investors wait too long to buy stocks, they're in danger of missing out on the inevitable rally.

Investors Should Consider This Warren Buffett Advice in 2023

AbbVie

Albertsons Companies

Broadcom

Bank of America

Casey's General Stores

Church & Dwight

Costco

Diageo

Dollar General

Flowers Foods

Home Depot

Coca-Cola

Kroger

Lowe's

McDonald's

NextEra Energy

NorthWestern

O'Reilly Automotive

Palo Alto Networks

PepsiCo

Procter & Gamble

UnitedHealth Group

VMware

Walmart

These recession-proof stocks typically hold up better in a recession and add diversity to your portfolio.

20 Recession-Proof Stocks to Buy Now for 2023

NEW YORK--( BUSINESS WIRE )--Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan's 41st Annual Healthcare Conference on Monday, January 9, 2023. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will make a formal presentation and answer questions about the company at 7:30 a.m. PST/10:30 a.m. EST.

Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference

NEW YORK--( BUSINESS WIRE )--Bristol Myers Squibb (NYSE: BMY) has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS.

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York

Abbott Labs

Archer-Daniels-Midland Company

Air Products and Chemicals

Apogee Enterprises

Booz Allen Hamilton Hld

Balchem

Franklin Resources

Blackrock Inc

Cincinnati Financial

CubeSmart

California Water Service Group

Enterprise Bancorp

Ecolab

Con Ed

Eastman Chemical

Fastenal

Franklin Electric

Graco

Kimberly-Clark

Mastercard

There were several double-digit boosts in December, with Mastercard and Eli Lilly leading the way with 16% and 15% increases, respectively. Abbott Labs began its second half-century of dividend growth with an 8.5% increase.

BlackRock, Kimberly-Clark Among 13 Companies To Start 2023 With Annual Dividend Increases

Automatic Data Processing

Aflac

Ameriprise Financial

A. O. Smith

Best Buy

Blackstone Group

Cardinal Health

CME Group

ConocoPhillips

CVS Health

Diamond Hill Investment Group

Duke Energy

Enterprise Products Partners

Fortune Brands Innovations Inc

Honeywell

Review of the current holdings and sectors in the portfolio, and how it has changed over the years. Income projections for 2023, and potential pitfalls.

2023 Dividend Growth Portfolio Review And Look Ahead

ABM Industries

Accenture Plc

Avient Corp

Broadridge Financial

Brady Corporation

Chubb

Churchill Downs

Chesapeake Utilities

Cisco Systems

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of January 1

News for Bristol-Myers Stock (BMY)